New drug aims to protect transplanted kidneys
NCT ID NCT06059664
First seen Apr 15, 2026 · Last updated Jun 19, 2026 · Updated 12 times
Summary
This study tests whether finerenone, a drug already used for kidney disease, can help protect transplanted kidneys. About 100 adults who received a kidney transplant 1 to 10 years ago will take either finerenone or a placebo daily for 12 months. Researchers will check how well the drug is tolerated and whether it improves kidney health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT; COMPLICATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UNC Eastowne Kidney Transplant Clinic
RECRUITINGChapel Hill, North Carolina, 27514, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Finerenone (Kerendia) oral tablet
What this could lead to
If successful, finerenone could become a new option to protect kidney function and reduce damage in transplant recipients, potentially delaying graft failure.
What could go wrong
This is an early Phase 2 trial with only 100 participants, so results may not apply broadly. Finerenone can raise potassium levels, requiring careful monitoring and dose adjustments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.